Castle Biosciences sales and marketing update

Castle launched its DecisionDx-EC in the U.S. to determine which patients with esophageal cancer will not benefit from chemoradiation prior to surgery. Esophageal cancer guidelines recommend chemotherapy and radiation, but according to the company data show about 25% of patients have tumors that are likely to be unresponsive to chemoradiation. ...